Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.34 |
| ▸ | GSK3B | P49841 | 6/20 | 0.34 |
| ▸ | RXRA | P19793 | 3/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | CDK4 | P11802 | 1/20 | 0.32 |
| ▸ | CCND3 | P30281 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | STK17B | O94768 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13014529 | 1.00 | TDO2 (0.35) | TDO2STK17AGSK3BRXRAGRIN1 | |
| SCHEMBL8026869 | 0.82 | STK17A (0.40) | TDO2STK17AGSK3BRXRAGRIN1 | |
| SCHEMBL3773612 | 0.77 | STK17A (0.44) | TDO2STK17AGSK3BRXRAGRIN1 | |
| SCHEMBL3776291 | 0.77 | STK17A (0.42) | TDO2STK17AGSK3BRXRAGRIN1 | |
| SCHEMBL3778561 | 0.76 | STK17A (0.42) | TDO2STK17AGSK3BRXRAGRIN1 | |
| SCHEMBL3776914 | 0.75 | KDR (0.42) | GSK3BCDK4JAK2 | |
| SCHEMBL3776913 | 0.75 | KDR (0.42) | GSK3BCDK4JAK2 | |
| SCHEMBL13014533 | 0.75 | KDR (0.42) | GSK3BCDK4JAK2 | |
| SCHEMBL27806962 | 0.73 | STK17A (0.40) | TDO2STK17AGSK3BRXRAGRIN1 | |
| SCHEMBL3772566 | 0.71 | STK17A (0.41) | TDO2STK17AGSK3BRXRAGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778974-B2 | Trisubstituted 1,2,4 triazoles | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-15 | — | — | US | disclosed |
| EP-2257535-B1 | TRISUBSTITUTED 1,2,4-TRIAZOLES AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-11-06 | — | — | EP | disclosed |
| US-20100324053-A1 | TRISUBSTITUTED 1,2,4 TRIAZOLES | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324053-A1 | TRISUBSTITUTED 1,2,4 TRIAZOLES | CHRNA1, CHRNA5, CHRNE | TDO2 1195/4885STK17A 1346/4885GSK3B 1284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.